Altogether, these data suggest that abnormalities in the fine-tuning of JAM-A expression at the post-transcriptional or post-translational level may be responsible for the observed JAM-A downregulation in CRC, rather than genetic or epigenetic events. The gene discussed is F11R; the disease is colorectal carcinoma.